SALT LAKE CITY, May 13, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will present data from 19 clinical studies at the 2015 American Society of Clinical Oncology annual meeting to be held May 29 to June 2, 2015 in Chicago, Ill. Key podium presentations will highlight new prospective research programs with advanced companion diagnostic and molecular diagnostic tests aimed at revolutionizing how we treat and prevent cancers. Abstracts of the Company's presentations are available at: abstracts.asco.org.
"Advances in personalized medicine will include selecting effective pharmaceuticals (companion diagnostics), preventing disease (hereditary caner tests) and in optimizing treatment decisions (prognostic tests). This meeting showcases our pioneering research in these three areas of personalized medicine. In companion diagnostics, the myChoice™ HRD test can transform the way we personalize treatment plans for ovarian and breast cancers today and many other cancers in the future," said Mark Capone, president Myriad Genetic Laboratories. "Another critical goal for personalized medicine is to prevent cancer. Our myRisk™ hereditary cancer panel test does just that by analyzing 25 genes associated with eight common hereditary cancers. Lastly, our prognostic tests demonstrate advances in optimizing treatments decisions in prostate cancer and lung cancer. As a pioneer in the field of personalized medicine, we remain firmly committed to scientific progress through outstanding research that can ultimately benefit patients."
The list of key Myriad presentations follows.
| 1. COMPANION DIAGNOSTIC PRESENTATIONS | |
| myChoice HRD™: Podium Presentation | |
| Title: | Prediction of pathological complete response (pCR) by homologous recombination deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: results from GeparSixto. |
| Presenter: | Gunter Von Minckwitz |
| Date: | Monday, June 1, 4:12 – 4:24 p.m. |
| Location | N Hall B1; Abstract: 1004 |
| myChoice HRD: Poster Discussion Sessions | |
| Title: | Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early stage breast cancer (NCT01372579). |
| Presenter: | Virginia Kaklamani |
| Date: | Saturday, May 30, 8:00 to 11:30 a.m. |
| Location: | N Hall B1; Abstract: 1017, Poster: 131 |
| Title: | Combined homologous recombination deficiency (HRD) scores and response to neoadjuvant platinum-based chemotherapy in triple negative and/or BRCA1/2 mutation associated breast cancer. |
| Presenter: | Melinda Telli |
| Date: | Saturday, May 30, 8:00 to 11:30 a.m. |
| Location: | N Hall B1; Abstract: 1018, Poster: 132 |
| myChoice HRD: Poster Sessions | |
| Title: | Reproducibility of homologous recombination deficiency (HRD) scores in biopsies of triple negative breast cancer (TNBC) tumors. |
| Presenter: | Kirsten Timms |
| Date: | Saturday, May 30, 8:00 to 11:30 a.m. |
| Location: | Abstract: 1091, Poster: 205 |
| Title: | Association of tumor BRCA1 reversion mutation arising during neoadjuvant platinum-based therapy in breast cancer (BC) with therapy resistance. |
| Presenter: | Anosheh Afghahi |
| Date: | Saturday, May 30, 8:00 to 11:30 a.m. |
| Location: | Abstract: 1094, Poster: 208 |
| Title: | Characteristics of homologous recombination deficiency (HRD) in paired primary and recurrent high-grade serous ovarian cancer (HGSOC). |
| Presenter: | Jai Patel |
| Date: | Saturday, May 30, 1:15 to 4:45 p.m. |
| Location: | Abstract: 5534, Poster: 92 |
| Title: | Use of homologous recombination deficiency (HRD) score to enriche for niraparib sensitive high grade ovarian tumors. |
| Presenter: | Keith Wilcoxen |
| Date: | Saturday, May 30, 1:15 to 4:45 p.m. |
| Location: | Abstract: 5532, Poster: 90 |
| Title: | Homologous recombination (HR) deficiency, tumor BRCA1/2 mutations (tmBRCA) and association with response and outcome following platinum monotherapy in high grade serous ovarian cancer (HGSOC). |
| Presenter: | Robert Brown |
| Date: | Saturday, May 30, 1:15 to 4:45 p.m. |
| Location: | Abstract: 5576, Poster: 134 |
| BRACAnalysis CDx™: Poster Session | |
| Title: | A randomized, placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with AZD 1775 (MK 1775) in women with recurrent, platinum-resistant epithelial ovarian, primary peritoneal or Fallopian tube cancers: Trial of Princess Margaret, Mayo, Chicago, and California consortia. |
| Presenter: | Stephanie Lheureux |
| Date: | Saturday, May 30, 1:15 to 4:45 p.m. |
| Location: | Abstract: TPS5613, Poster: 167a |
| 2. HEREDITARY CANCER PRESENTATIONS | |
| myRisk™ Hereditary Cancer: Podium Presentation | |
| Title: | Predisposing germline mutations in high grade ER+HER2- breast cancer (BC) patients diagnosed <age 50. |
| Presenter: | Judy Garber |
| Date: | Saturday, May 30, 2:15 to 2:27 p.m. |
| Location: | S 100BC; Abstract: 1503 |
| myRisk Hereditary Cancer: Poster Discussion Sessions | |
| Title: | Outcomes of clinical testing for 50,000 patients utilizing a panel of 25 genes associated with increased risk for breast, ovarian, colorectal, endometrial, gastric, pancreatic, melanoma and prostate cancers. |
| Presenter: | Eric Rosenthal |
| Date: | Monday, June 1, 1:15 to 4:45 p.m. |
| Location: | S102, Abstract: 1515, Poster: 338 |
| Title: | Assessment of the clinical presentation for patients discovered to have at least two deleterious mutations on multigene panel testing. |
| Presenter: | Jeff Weitzel |
| Date: | Monday, June 1, 1:15 to 4:45 p.m. |
| Location: | S102, Abstract: 1514, Poster: 337 |
| myRisk Hereditary Cancer: Poster Session | |
| Title: | A study of triple-negative breast cancer patients tested with a 25-gene panel of hereditary cancer genes. |
| Presenter: | John Sandbach |
| Date: | Saturday, May 30, 8:00 to 11:30 a.m. |
| Location: | Abstract: 1067, Poster: 181 |
| Title: | Multi-gene panel testing in an unselected endometrial cancer cohort. |
| Presenter: | Kari Ring |
| Date: | Monday, June 1, 1:15 to 4:45 p.m. |
| Location: | Abstract: 1533, Poster: 357 |
| 3. PROGNOSTIC TEST PRESENTATIONS | |
| myPlan® Lung Cancer: Poster Session | |
| Title: | Validation of a cell cycle progression score for 5-year mortality risk in patients with stage I non-small cell lung cancer. |
| Presenter: | Takashi Eguchi |
| Date: | Monday, June 1, 8:00 to 11:30 a.m. |
| Location: | Abstract: 7522, Poster: 269 |
| Prolaris®: Poster Session | |
| Title: | Performance of CCP assay in an updated series of biopsy samples obtained from commercial testing. |
| Presenter: | John Davis |
| Date: | Saturday, May 30, 1:15 to 4:45 p.m. |
| Location: | Abstract: 5033, Poster: 25 |
| Prolaris: Abstract Publications | |
| Title: | Validation of an active surveillance threshold for the CCP score in conservatively managed men with localized prostate cancer. |
| Author: | Jack Cuzick. Abstract: e16040 |
| Title: | Impact of CCP test on personalizing treatment decisions: results from a prospective registry of newly diagnosed prostate cancer patients. |
| Author: | Neal Shore. Abstract: e16042 |
| Title: | Evaluation of the economic impact of the CCP assay in localized prostate cancer. |
| Author: | David Crawford. Abstract: e16037 |
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions, and assess risk of disease progression and recurrence. Myriad is focused on strategic initiatives to grow existing markets, diversify through the introduction of new products, including companion diagnostics, and expand internationally. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan Lung Cancer, BRACAnalysis CDx, MyChoice HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the presentation of new clinical data on myChoice HRD, myRisk Herditary Cancer, BRACAnalysis CDx, Prolaris and myPlan Lung Cancer at the ASCO 2015 meeting; the ability of our new companion diagnostic tests, such as myChoice™ HRD, to transform the way we personalize treatment plans for ovarian and breast cancers today and many other cancers in the future; the ability of our myRisk™ hereditary cancer panel test to help prevent cancer; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing to new testing services, including unexpected costs and delays; risks related to decisions or changes in the governmental or private insurers' reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A of in our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2014, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.